CytoMed Therapeutics

Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. 

CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers.

iPSCbank

IPSC Depository Sdn Bhd and IPSCBank Pte Ltd (iPSCbank) are subsidiaries of CytoMed Therapeutics which mainly focus on the banking of our customers’ cells such as Peripheral Blood Mononuclear Cells (PBMCs), induced Pluripotent Stem Cells (iPSCs) and Mesenchymal Stem Cells (MSCs) for future usage.


Follow us for more updates